The FLAG1 study will assess the diagnostic performance of biomarkers Glutathion S-Transferase-π (GST-π) and Peroxyredoxin 1 (PRDX1) to identify cerebral infarction of less than 4,5 hours in a population of patients with neurological deficiency of less than 12 hours.

Inclusion Criteria:

• Patients over 18 years old

• Patients with symptoms consistent with stroke and a National Institute of Health Stroke Score ≥3 at the inclusion time

• Time symptom onset ≤ 24 hours at inclusion:

  • For patients with time of symptom onset is <4.5h at inclusion, the time of symptom onset has to be precisely known, with a margin of error not exceeding 30 minutes (through patient or witness interview)
  • For patients with time of symptom onset is >4.5h at inclusion, knowledge of precise time of symptom onset is not required. For these patients, to ensure onset-to-inclusion time is between 4.5 and 24 hours at inclusion:

• last time patient presented no deficit must be less than 24 hours,

• symptoms must have been first recognized more than 4.5 hours before blood draw.

• Possibility to perform MRI within the 30 minutes following blood collection

• Person affiliated to or beneficiary of a social security plan

Exclusion Criteria:

• Persons referred in articles L.1121-5, L.1121-7, L.1121-8 and L.1122-2 of the French Public Health Code: Pregnant, parturient or breastfeeding woman ; Minor person (non-emancipated) ; Adult person under legal protection (any form of public guardianship) ; Adult person incapable of giving consent and not under legal protection.
• Persons deprived of liberty for judicial or administrative decision.
• Persons subject to psychiatric care under articles L.3212-1 and L.3213-1 of the French Public Health Code.
• Known cancer in progression.
• Known cirrhosis.
• Myocardial Infarctions, stroke, Subarachnoid hemorrhage or intracranial injury within 3 months prior to enrolment.